
Marguerite Ennis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7705074/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. New England Journal of Medicine, 2001, 345, 1719-1726.	27.0	819
2	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2002, 20, 42-51.	1.6	798
3	Risk of Menopause During the First Year After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2365-2365.	1.6	503
4	Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3757-3763.	1.6	305
5	Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 120-120.	1.6	278
6	Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. Clinical Breast Cancer, 2008, 8, 501-505.	2.4	214
7	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 2012, 135, 821-830.	2.5	213
8	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. Journal of Clinical Oncology, 2012, 30, 164-171.	1.6	180
9	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Research and Treatment, 2012, 134, 769-781.	2.5	165
10	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. Journal of Clinical Oncology, 2012, 30, 19-26.	1.6	134
11	Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology, 2003, 21, 1944-1951.	1.6	124
12	Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology, 2010, 28, 5147-5152.	1.6	106
13	Quality of Life in Long-Term Breast Cancer Survivors. Journal of Clinical Oncology, 2013, 31, 3540-3548.	1.6	102
14	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Research and Treatment, 2002, 74, 65-76.	2.5	98
15	Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. Journal of Clinical Oncology, 2004, 22, 4184-4192.	1.6	98
16	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Research and Treatment, 2007, 106, 39-47.	2.5	92
17	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research, 2015, 17, 32.	5.0	92
18	Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. Journal of Clinical Oncology, 2003, 21, 2500-2507.	1.6	84

MARGUERITE ENNIS

#	Article	IF	CITATIONS
19	Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	7.4	81
20	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Research and Treatment, 2009, 114, 517-525.	2.5	77
21	Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. Journal of Clinical Oncology, 2005, 23, 6037-6042.	1.6	76
22	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
23	Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2013, 141, 331-339.	2.5	70
24	Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatment, 2005, 94, 135-144.	2.5	62
25	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50
26	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Research and Treatment, 2010, 122, 647-659.	2.5	37
27	Economic Analysis of Psychosocial Group Therapy in Women with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 183-190.	2.5	32
28	Sexual health in long-term breast cancer survivors. Breast Cancer Research and Treatment, 2018, 172, 159-166.	2.5	29
29	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Journal of the National Cancer Institute, 2021, 113, 192-198.	6.3	24
30	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. Breast Cancer Research and Treatment, 2012, 134, 759-767.	2.5	16
31	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
32	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment, 2017, 164, 451-460.	2.5	15
33	Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
34	Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis. Npj Breast Cancer, 2021, 7, 97.	5.2	14
35	Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Research and Treatment, 2013, 141, 485-493.	2.5	13
36	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11

MARGUERITE ENNIS

#	Article	IF	CITATIONS
37	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
38	Prophylactic cranial irradiation (PCI). Still a no-brainer?. Lung Cancer, 2015, 89, 4-7.	2.0	6
39	Prognostic associations of plasma hepcidin in women with early breast cancer. Breast Cancer Research and Treatment, 2020, 184, 927-935.	2.5	5
40	Cancer Antigen 15-3/Mucin 1â€,Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
41	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy Journal of Clinical Oncology, 2019, 37, 529-529.	1.6	3
42	CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC) Journal of Clinical Oncology, 2018, 36, 557-557.	1.6	2
43	Association of obesity with breast cancer outcome in relation to cancer subtypes Journal of Clinical Oncology, 2019, 37, 11557-11557.	1.6	1
44	Post-surgical highly sensitive C-reactive protein (hsCRP) and prognosis in early stage in breast cancer (BC) Journal of Clinical Oncology, 2013, 31, 550-550.	1.6	0
45	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , .	6.3	Ο